APLT Applied Therapeutics Inc.

20.92
-0.58  -3%
Previous Close 21.5
Open 20.92
Price To Book 12.6
Market Cap 387,324,051
Shares 18,514,534
Volume 101,514
Short Ratio
Av. Daily Volume 33,923
Stock charts supplied by TradingView

NewsSee all news

  1. Applied Therapeutics Announces Presentation of Pre-Clinical Data Highlighting AT-001 for Treatment of Diabetic Cardiomyopathy at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

    NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in

  2. Applied Therapeutics Announces Presentations Outlining the Design and Rationale for the ARISE-HF Pivotal Study of AT-001 for Treatment of Diabetic Cardiomyopathy at the 16th Annual Global Cardiovascular Clinical Trialist's Forum (CVCT)

    NEW YORK, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in

  3. Applied Therapeutics Announces Presentation of Clinical Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy at the American Heart Association (AHA) Scientific Sessions 2019

    NEW YORK, Nov. 15, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in

  4. Applied Therapeutics Reports Third Quarter 2019 Financial Results

    NEW YORK, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing novel drug candidates in indications of high unmet medical need, today

  5. Applied Therapeutics, Inc. Announces Pricing of $20 Million Private Placement of Common Stock

    NEW YORK, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT) (the "Company"), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial initiation announced September 4, 2019.
AT-001
Diabetic cardiomyopathy (DbCM)
Phase 1 additional data due 4Q 2019.
AT-007
Galactosemia

Latest News

  1. Applied Therapeutics Announces Presentation of Pre-Clinical Data Highlighting AT-001 for Treatment of Diabetic Cardiomyopathy at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

    NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in

  2. Applied Therapeutics Announces Presentations Outlining the Design and Rationale for the ARISE-HF Pivotal Study of AT-001 for Treatment of Diabetic Cardiomyopathy at the 16th Annual Global Cardiovascular Clinical Trialist's Forum (CVCT)

    NEW YORK, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in

  3. Applied Therapeutics Announces Presentation of Clinical Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy at the American Heart Association (AHA) Scientific Sessions 2019

    NEW YORK, Nov. 15, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in

  4. Applied Therapeutics Reports Third Quarter 2019 Financial Results

    NEW YORK, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing novel drug candidates in indications of high unmet medical need, today

  5. Applied Therapeutics, Inc. Announces Pricing of $20 Million Private Placement of Common Stock

    NEW YORK, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT) (the "Company"), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated

  6. Applied Therapeutics to Present Preclinical Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD)

    NEW YORK, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in

  7. Applied Therapeutics to Present Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy at the Heart Failure Society of America (HFSA) 23rd Annual Scientific Meeting

    NEW YORK, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in